Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Clinical trial NCT02898259 · TERMINATED
Trial details
- NCT number
- NCT02898259
- Sponsor
- Brian Hill
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-20
- Primary completion
- 2018-10-23
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.